Cisplatin Cardiac Side Effects
Cisplatin causes arterial thrombosis with myocardial ischemia in approximately 2% of patients acutely, and carries a long-term absolute risk of coronary artery disease up to 8% over 20 years, particularly in testicular cancer survivors. 1, 2
Primary Cardiac Toxicities
Acute Vascular Events
Cisplatin induces arterial thrombosis through procoagulant effects and direct endothelial toxicity, leading to:
- Myocardial infarction
- Cerebrovascular accidents
- Thrombotic microangiopathy (hemolytic-uremic syndrome)
- Cerebral arteritis
The FDA label explicitly warns that these vascular toxicities can occur when cisplatin is combined with other antineoplastic agents 3. The mechanisms are multifactorial, involving procoagulant status and direct endothelial injury 1, 2.
Arrhythmias
Cardiac abnormalities are documented in the FDA labeling, including:
- Bradycardia - can be severe and symptomatic 3, 4, 5
- Tachycardia (particularly during anaphylactic-like reactions) 3
- Atrioventricular block - rare but can progress to complete heart block requiring permanent pacemaker placement 4
Two case reports demonstrate that cumulative cisplatin doses >240 mg/m² represent a risk factor for developing AV block 4. Patients presenting with dyspnea without chest pain during cisplatin therapy should be evaluated for arrhythmic complications.
Long-Term Cardiovascular Disease
Cisplatin-treated testicular cancer survivors face a greater than 2-fold increased risk of coronary artery disease appearing 10+ years post-treatment, with an absolute 20-year risk of up to 8% for ischemic events 1, 2. This risk is amplified when cisplatin is combined with radiation therapy or in patients with pre-existing cardiovascular risk factors.
Clinical Management Approach
Pre-Treatment Assessment
Before initiating cisplatin, evaluate:
- Baseline cardiovascular risk factors - hypertension, diabetes, dyslipidemia, smoking
- Cardiac function - LVEF assessment if high-risk features present
- Renal function - creatinine clearance must be adequate (typically ≥60 mL/min for full-dose cisplatin) 6
- Prior radiation exposure - particularly mediastinal radiation
During Treatment Monitoring
- Maintain strict control of cardiovascular risk factors throughout therapy 1
- Monitor for symptoms: dyspnea without chest pain may indicate arrhythmia rather than ischemia 4
- ECG monitoring if symptomatic bradycardia, chest discomfort, or palpitations develop
- Electrolyte monitoring - hypomagnesemia and hypocalcemia can exacerbate arrhythmias 3
Management of Cardiac Toxicity
If myocardial ischemia occurs:
- Discontinue cisplatin immediately
- Evaluate for acute coronary syndrome with troponin, ECG, echocardiography
- Exclude ischemic heart disease as comorbidity 7
- Consider cardiology consultation, preferably cardio-oncology specialist 7
If significant arrhythmia develops:
- Obtain 12-lead ECG and continuous telemetry monitoring
- Correct electrolyte abnormalities (magnesium, calcium, potassium) 3
- For symptomatic bradycardia or high-degree AV block: temporary pacing may be required; permanent pacemaker if persistent 4
- For AV block requiring pacemaker: cisplatin should be discontinued 4
If LVEF decline occurs:
- If LVEF decreases ≥10% to a value <50%: initiate ACE inhibitors (or ARBs) plus beta-blockers unless contraindicated 1, 2
- Cardiology consultation mandatory 7
- Consider cardiac biomarkers (BNP/NT-proBNP, troponin) for ongoing monitoring 7
Long-Term Surveillance
For cisplatin-treated cancer survivors, particularly testicular cancer patients:
- Aggressive cardiovascular risk factor modification is essential
- Consider screening for coronary artery disease starting 5-10 years post-treatment
- Monitor for late-onset cardiac complications up to 20-30 years after exposure 1, 2
Critical Pitfalls to Avoid
Do not dismiss dyspnea as anxiety or pulmonary toxicity - always consider cardiac arrhythmia, especially with cumulative doses >240 mg/m² 4
Do not overlook electrolyte disturbances - hypomagnesemia and hypocalcemia are common with cisplatin and can precipitate or worsen arrhythmias 3
Do not ignore subtle cardiac symptoms - cisplatin-induced ischemia may present atypically, and silent ischemia is possible 1, 2
Do not use aluminum-containing needles or IV sets - aluminum reacts with cisplatin causing precipitate formation 3
Anaphylactic-like reactions can mimic cardiac events - facial edema, wheezing, tachycardia, and hypotension can occur within minutes of administration; have epinephrine, corticosteroids, and antihistamines immediately available 3